BACKGROUND: Japan Clinical Oncology Group (JCOG) defined gastric cancer (GC) with bulky lymph node (Bulky N) and/or para-aortic lymph node (PAN) as extensive lymph node metastasis (ELM), and has developed neoadjuvant chemotherapy followed by D2 gastrectomy with PAN dissection (PAND) through three phase II trials using different regimens (JCOG0001: irinotecan/cisplatin, JCOG0405: cisplatin/S-1, JCOG1002: docetaxel/cisplatin/S-1). However, whether PAND provides survival benefit remains uncertain. METHODS: The therapeutic value index was investigated using integrated data from JCOG0001, JCOG0405, and JCOG1002. Patients were classified into Bulky N group (only bulky N without PAN) and PAN group (PAN regardless of bulky N) based on the clinical diagnosis. The index was calculated by multiplication of incidence of metastasis and percentage 5-year relapse-free survival (5yRFS) of patients with metastasis for each lymph node area. RESULTS: A total of 122 patients were analyzed (Bulky N group: 68, PAN group: 54). In Bulky N group, the proportion of metastasis/5yRFS/index in the PAN area was 15.2%/30.0%/4.5 (JCOG0001: 27.8%/20.0%/5.6, JCOG0405: 13.6%/33.3%/4.5, JCOG1002: 7.7%/50.0%/3.8). The proportion of metastasis decreased across trials. In PAN group, the proportion of metastasis/5yRFS/index in the PAN area was 44.4%/4.2%/1.9 (JCOG0001: 81.3%/7.7%/6.3, JCOG0405: 30.0%/0.0%/0.0, JCOG1002: 27.8%/0.0%/0.0). Notably, the indices of the recent two trials were zero. CONCLUSIONS: PAND may retain a potential role in the Bulky N group, whereas its benefit appears limited in the PAN group. Decreasing trends in PAN metastasis and therapeutic value were observed in both groups. Given the distinct characteristics of these subgroups, the omission of PAND should be determined through separate future validation.
Advancements in cancer treatment have iproved the long-term prognosis, leading to an increasing number of cancer survivors with coexisting heart failure (HF). Cardiovascular (CV) death is one of the major causes of death among cancer survivors with HF, highlighting the crucial need for risk stratification for CV death to improve their long-term prognosis. However, the specific risk factors for CV death in cancer survivors with HF are not fully understood. We enrolled 485 cancer survivors who were admitted to our hospital for treatment of HF between 2011 and 2023. All patients were prospectively followed up for a median period of 545 days with the endpoint of all-cause death. During the follow-up period, there were 107 CV deaths, which accounted for more than half of the total deaths and were four times higher than cancer deaths. Multivariate Fine-Gray analysis showed that low serum albumin levels independently predicted CV death after adjustment for confounding factors (sub-distribution hazard ratio [sHR], 0.740 per 1-SD increase; 95
While neoadjuvant immunochemotherapy has improved outcomes of resectable nonsmall cell lung cancer (NSCLC), treatment-induced tissue changes can increase surgical complexity. This study aimed to identify preoperative predictors of technically challenging surgery following neoadjuvant immunochemotherapy. This multicenter retrospective analysis included 114 patients who underwent surgery after neoadjuvant nivolumab plus platinum-based chemotherapy at 29 institutions between March 2023 and July 2024. Challenging surgery was defined as one requiring bronchoplasty, pulmonary artery angioplasty, or pneumonectomy. Logistic regression was used to identify preoperative predictors for surgical complexity. Twenty-one patients (18.4
BACKGROUND:We estimated net survival trends for patients with stomach cancer registered in 16 regional population-based cancer registries in Japan that participated in the CONCORD-3 study. METHODS:We included data on adults (15-99 years) diagnosed with stomach cancer between 2000 and 2014 and followed-up for their vital status until 31 December 2014. We grouped cancer patients into three anatomic groups (proximal, distal, and overlapping regions and stomach cancer, not otherwise specified) with the International Classification of Disease for Oncology, Third edition topography codes. We estimated 5-year net survival with the Pohar Perme estimator for three calendar periods (2000-2004, 2005-2009, 2010-2014), by age group (15-44, 45-54, 55-64, 65-74, and 75-99 years), anatomic group, and stage at diagnosis. All-ages survival estimates were age-standardized using the International Cancer Survival Standard weights. RESULTS:Five-year net survival improved over time, from 50.5% in 2000-2004 to 57.6% and 60.3% in 2005-2009 and 2010-2014, respectively. Survival for patients with proximal stomach cancer improved from 49.7% in 2000-2004 to 53.5% 2005-2009 and plateaued to 53.1% in 2010-2014. Survival for distal stomach cancer increased from 64.8% in 2000-2004 to 67.6% and 68.2% in 2005-2009 and 2010-2014, respectively. In 2010-2014, 5-year net survival for patients with localized disease (94.8%) was much higher than survival for regional (53.7%) and distant (6.4%) disease. CONCLUSIONS:Five-year net survival for stomach cancer improved noticeably during 2000-2014. This improvement might be due to advances in systemic chemotherapy. Although survival in distal stomach cancer had improved, no such improvement was seen in proximal stomach cancer. Standardizing esophagogastric junction cancer treatment may improve its outcomes and contribute to better survival in proximal stomach cancer overall. Scientific evaluation of screening programs is also needed to enhance the efficacy of stomach cancer control initiatives in Japan.
BACKGROUND:With the widespread adoption of immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC), local recurrence after immunotherapy has become increasingly frequent. However, limited evidence is available regarding salvage surgery after ICI therapy. METHODS:A multi-institutional retrospective study (CReGYT-05 Immune Checkpoint Inhibitor-Salvage Study) was conducted across 14 centers in Japan, evaluating patients who underwent salvage surgery after ICI therapy between 2016 and 2023. Salvage surgery was classified as conversion surgery (downstaging from initially unresectable to resectable disease) or true salvage surgery (surgery for local recurrence or residual disease). The primary endpoints included perioperative outcomes, overall survival (OS), and recurrence-free survival (RFS). RESULTS:The study analyzed 32 patients. Radiologic response to ICI therapy showed complete response in 4 patients (12.5 %), partial response in 23 patients (71.9 %), and stable disease in 5 patients (15.6 %). Salvage procedures comprised true salvage surgery (n = 17, 53.1 %) and conversion surgery (n = 15, 46.9 %). Lobectomy was performed for 84.4 % of the patients. Perioperative complications occurred in eight (25.0 %) of the patients, with no perioperative mortality. Pathologic complete response was achieved for six (18.8 %) patients. The 3- and 5-year OS rates from the initial diagnosis were 86.9 % and 77.2 %, respectively. Conversion surgery demonstrated superior 3-year RFS compared with true salvage surgery (92.8 % vs 36.3 %; p = 0.010). Univariable analysis identified salvage type as a significant factor for RFS. CONCLUSIONS:Salvage surgery after ICI therapy can be safely performed and is associated with encouraging survival outcomes for carefully selected patients, particularly those undergoing conversion surgery.